Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6661380 | 1.00 | KCNH2 (0.87) | KCNH2 | |
| SCHEMBL6659264 | 1.00 | KCNH2 (0.87) | KCNH2 | |
| SCHEMBL6659272 | 1.00 | KCNH2 (0.87) | KCNH2 | |
| SCHEMBL6661376 | 1.00 | KCNH2 (0.87) | KCNH2 | |
| SCHEMBL6705069 | 1.00 | KCNH2 (0.87) | KCNH2 | |
| SCHEMBL6323427 | 0.93 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL5853749 | 0.93 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL5854175 | 0.93 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL6606141 | 0.93 | KCNH2 (1.00) | KCNH2 | |
| SCHEMBL6605607 | 0.92 | KCNH2 (0.86) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6806277-B2 | ANTIBACTERIAL AGENTS; HEMOPHILUS INFLUENZA; METICILLIN RESISTANT STAPHYLOCOCCUS AUREUS AS5155; STREPTOCOCCUS PNEUMONIAE 6254-01; ENTEROCOCCUS FAECIUM ATCC29212 OR H983401; MORAXELLA CATHARRHALIS IPA152 | AVENTIS, PHARMA S.A. (FR) | 2004-10-19 | — | — | US | disclosed |
| US-20040058919-A1 | Quinolylpropylpiperidine derivatives, preparation process and intermediates, and compositions including them | AVENTIS PHARMA S.A. (FR) | 2004-03-25 | — | — | US | disclosed |
| WO-2004011454-A2 | QUINOLYL PROPYL PIPERIDINE DERIVATIVES, PREPARATION METHOD AND INTERMEDIATES AND COMPOSITIONS CONTAINING SAME | AVENTIS PHARMA S.A. (FR) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058919-A1 | Quinolylpropylpiperidine derivatives, preparation process and intermediates, and compositions including them | OGFOD1, CBR3, AOC3 | KCNH2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.